TopPic

Members

image of Stefan Knapp Prof Stefan Knapp
Email: knapp (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29871

Stefan studied Chemistry at the University of Marburg (Germany) and at the University of Illinois (USA). He did his PhD in protein crystallography at the Karolinska Institute in Stockholm (Sweden) (1996) and continued his career at the Karolinska Institute as a postdoctoral scientist (1996-1999). In 1999, he joined the Pharmacia Corporation as a principal research scientist in structural biology and biophysics. He left the company in 2004 to set up a research group at the Structural Genomics Consortium at Oxford University (SGC). From 2008 to 2015 he was a Professor of Structural Biology at the Nuffield Department of Clinical Medicine (NDM) at Oxford University (UK) and between 2012 and 2015 he was the Director for Chemical Biology at the Target Discovery Institute (TDI). He joined Frankfurt University (Germany) in 2015 as a Professor of Pharmaceutical Chemistry and the Buchmann Institute of Molecular Life Sciences. He remains associated to the SGC as a visiting Professor at Oxford and he is also adjunct Professor of the George Washington University. Since 2017 he is the CSO of the newly founded SGC node at the Goethe-University Frankfurt. His research interests are the rational design of selective inhibitors that target protein kinases as well as protein interactions modules that function as reader domains of the epigenetic code.

image of a group member Susanne Müller-Knapp
Email: susanne.mueller-knapp (at) bmls.de
Tel: +49 (0)69 798-42535

Knapp studied Human Biology in Marburg Germany followed by a PhD in molecular biology at the Karolinska Institute in Stockholm, Sweden (1997). She then had more than 6 years of postdoctoral training in the area of inflammation and gene regulation at the Karolinska Institute and at the DIBIT San Raffaele Scientific Institute in Milan, Italy.
In 2004 Susanne joined the Structural Genomics Consortium, SGC, in Oxford. The SGC is an international public private partnership that currently comprises 8 international pharmaceutical companies and a large network of academic and industrial collaborators. Susanne worked at the SGC first as External Research Manager and then Scientific Coordinator. She has been the Project Manager of the Epigenetic Probe Project, which generates tool compounds with defined specificity and selectivity for epigenetic targets and the cell based assay group at the SGC in Oxford testing the cellular activity of the in vitro characterised tool compounds. In her role as Chief Operating Officer at the SGC Frankfurt Susanne is now coordinating several probe programs including the global SGC kinase chemical probe program and the donated probe program, which makes probes available from the pharmaceutical partners of the SGC.

image of a group member Rosa Aghighi
Email: r.aghighi (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-42701

Rosa Aghighi studied pharmacy at the Goethe University in Frankfurt. After completing her studies, she joined the group of Stefan Knapp where she worked on the thermodynamics of hinge-binders and a database of kinase inhibitors. Her current work in the group is focused on selectivity mechanisms of kinase inhibitors in structural biology.

image of a group member Jennifer Amrhein
Email: amrhein (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29874

Jennifer Amrhein graduated with a Master´s degree in Chemistry at the Johann Wolfgang Goethe University in Frankfurt am Main in 2018. The research topic of her master thesis was the "synthesis and structure optimization of macrocyclic kinase inhibitors". Since February 2019, she is developing macrocyclic kinase inhibitors in the group of Stefan Knapp at the SGC site Frankfurt.

image of a group member To Dinh Nguyen Ngu
Email: To (at) pharmchem.uni-frankfurt.de

In December 2020 To Dinh Nguyen Ngu joined Prof. Knapp's group as technical assistance.

image of a group member Dimitrios-Ilias Balourdas
Email: Balourdas (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29915

Dimitrios-Ilias Balourdas obtained his Pharmacy diploma degree from the National and Kapodistrian University of Athens in 2019. He completed his MSc dissertation at Goethe University Frankfurt in the group of Prof. Stefan Knapp, within the framework of the Erasmus+ program. His work focused on the characterization of dual BET/HDAC inhibitors for the treatment of pancreatic ductal adenocarcinoma. Later in 2019, he was awarded a DAAD research grant to establish a collaboration project between Prof. Vassilis Gorgoulis (Athens) and Prof. Stefan Knapp to elucidate the function of CDC6, a novel drug target involved in carcinogenesis and cellular senescence. In August 2020, Ilias has joined the SGC Frankfurt as a PhD student working on targeting transcription factors, initially funded by a Buchmann fellowship.

image of a group member Nicolas Bauer
Email: bauer (at) chemie.uni-frankfurt.de
Tel: +49 (0)69 798-29496

Nicolas Bauer graduated with a master’s degree in chemistry at the Johann Wolfgang Goethe University in Frankfurt am Main in 2019. During his master thesis, he focused on the development and synthesis of dual BET/HDAC inhibitors. In May 2019, he joined the group of Prof. Stefan Knapp as a PhD student. His current research is focused on targeting epigenetic reader domains

image of a group member Benedict-Tilman Berger
Email: b.berger (at) chemie.uni-frankfurt.de
Tel: +49 (0)69 798-42521

Benedict-Tilman Berger studied Biochemistry at the Freie Universität Berlin. Both his Bachelor thesis (Bayer HealthCare, Department of Screening) and his Master thesis (SGC Oxford, Department of Protein Kinases and Chemical/Structural Biology) focused on binding kinetics of protein kinase inhibitors and possible structural explanations for a slow binding of compounds, which might be a parameter for drug optimization in terms of selectivity, safety or dosing intervals. In 2016, he joined the group of Prof. Stefan Knapp at the SGC site in Frankfurt am Main to work on his PhD thesis that he finished in 2020. He was following up on his previous work on kinases, using more advanced techniques, e.g., the NanoBRET cellular target engagement assay, to explain in vitro and in vivo binding kinetics of kinase-ligand interactions on a structural level. Currently, he is contributing to a consortium (SFB 1399) that aims to identify new epigenetic targets in small cell lung cancer with cellular screening and helps setting up a kinome-wide NanoBRET screening platform.

image of a group member Jelena Bozilovic
Email: bozilovic (at) chemie.uni-frankfurt.de
Tel: +49 (0)69 798-29800

Jelena obtained her PhD from the Institute of Organic Chemistry and Chemical Biology at Goethe University Frankfurt in 2008, followed by postdoctoral work at the same institute. The main focus of her work was on the development of synthetic oligonucleotides for therapeutic use (antisense oligonucleotides and RNAi). She also played a leading role in setting up a start-up company developing methods for analyzing viral genotypes. In 2016, she joined the group of Prof. Knapp as a medicinal chemist and is currently working on the synthesis and development of molecules for the targeted degradation of kinases and bromodomains in cancer therapy (PROTACs).

image of a group member Ralf Braden
Email: braden (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29315

Ralf Braden started his training as chemical lab technician in 1985 at the Hoechst AG in Frankfurt. In the following 30 years, after finishing his apprenticeship, he worked for Hoechst AG, Trevira, Clariant, WeylChem and Samsung. In 2015 he joined the Group of Stefan Knapp at Goethe University.

image of a group member Apirat Chaikuad
Email: chaikuad (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29401

Apirat Chaikuad is a senior scientist at Frankfurt University. He studied biology at Chulalongkorn University (Thailand) and later did a PhD in structural biology at University of Bristol (UK). He joined the Structural Genomics Consortium at the University of Oxford in 2008 to work with Frank von Delft in the crystallography team. During this time, he successfully developed the newly-minimized BCS crystallization screen by incorporating a novel defined PEG smears method, which is now commercially available. He was also awarded the Emanoel Lee Junior Research Fellowship from St Cross College and a merit award from University of Oxford. Later, he has joined the team of Prof. Stefan Knapp. His current research interests focus primarily on structural biology and chemical biology of signaling pathway, essentially protein kinases.

image of a group member Deep Chatterjee
Email: chatterjee (at) nmr.uni-frankfurt.de
Tel: +49 (0)69 798-29872

Deep Chatterjee received his Master's degree in Microbiology from University of Calcutta, Kolkata, India. He then moved to Goethe-Universität Frankfurt, Germany for his doctoral studies, with a focus on NMR characterization of membrane and soluble proteins. In 2017, he joined the group of Prof. Stefan Knapp as a postdoc. He is funded by the Michael J. Fox Foundation to study the protein kinase LRRK2, which is involved in Parkinson's disease.

image of a group member Verena Dederer
Email: Dederer (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-42524

Verena received her Diploma in technical biology from the University of Stuttgart. She completed her thesis with Prof. Daniel Finley at Harvard Medical School on the topic of protein degradation during erythropoiesis. After that, Verena pursued her PhD at University of Heidelberg studying the cellular function of intramembrane proteases and AAA-ATPases and their role in membrane protein homeostasis. Verena joined the group of Prof. Stefan Knapp in January 2021 as a post-doc to study protein kinases related to Parkinson’s disease.

image of a group member Anja Dölle
Email: doelle (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29915

Anja Dölle obtained a Bachelor’s degree in chemistry from the university of Würzburg in 2015, followed by a Master’s degree from the University of Frankfurt in 2017. During her master thesis she focused on the synthesis of PROTAC molecules to target bromodomain containing proteins. In April 2018, she started her PhD in the lab of Prof. Stefan Knapp at the Institute of Pharmaceutical Chemistry, working on the development of PROTAC molecules to validate the inhibition of oncoprotein MYC. Her research is funded by the federal ministry of education and research of Germany.

image of a group member Lewis Elson

Lewis Elson graduated with a Master’s degree in Molecular Cell Biology from Nottingham Trent University in 2018 where the research topic of his thesis was determining the effect of acetylation on the de novo methyltransferases DNMT3A and DNMT3B. Following graduation, he was employed at the contract research organisation Covance within Safety Assessment Toxicology. His duties involved study coordination and assessing the toxicological profiles of potential pharmaceuticals in both primate and rodent models. Lewis joined SGC Frankfurt in December of 2020 as a Technical Assistant for the Cellular Assays working group.

image of a group member Joshua Gerninghaus
Email: gerninghaus (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29313

Joshua Gerninghaus studied pharmacy at Johann Wolfgang Goethe University in Frankfurt. After finishing his studies he worked on CK2 inhibitors in Knapp Group for six months before graduating with pharmacy state examination in December 2019. In February 2020 he started his PhD. The current focus of his work is on development of selective macrocyclic kinase inhibitors.

image of a group member Francesco Aleksy Greco
Email: greco (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29313

Francesco Aleksy Greco studied pharmacy at the Goethe University of Frankfurt. After graduating in 2018 he worked 6 months on CLK inhibitors in Stefan Knapps group. He eventually joined the group as a PhD student in February 2019. The current topic of interest is the development of allosteric kinase inhibitors.

image of a group member Thomas Hanke
Email: hanke (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29313

Thomas Hanke studied Pharmacy at the Goethe University in Frankfurt. In 2014, he completed his PhD in the field of pharmaceutical chemistry, investigating the synthesis and pharmacological characterization of dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors as a new alternative strategy for anti-inflammatory drugs. In 2015, he joined Stefan Knapp´s group where he is working on the development of chemical probes for targeting kinases. For that, he is pursuing different strategies, including the synthesis of allosteric kinase inhibitors (e.g. for LIMK1/2) and the synthesis of macrocyclic compounds to generate new chemistry for targeting kinases.

image of a group member Andreas C. Joerger
Email: joerger (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29872

Andreas C. Joerger obtained his doctoral degree from the University of Freiburg, Germany in 2000 for elucidating the reaction mechanism and structural basis of substrate specificity of a zinc-dependent aldolase. He then assumed a postdoc position in the group of Prof. Sir Alan Fersht at the Medical Research Council (MRC) Centre for Protein Engineering in Cambridge, United Kingdom, initially working on protein design. He stayed on as a senior scientist in structural biology until 2010, before moving to the MRC Laboratory of Molecular Biology in Cambridge (2010-2015). During his long spell at the MRC, he made key contributions towards unraveling the complex structural biology of the tumor suppressor p53 and related proteins. He determined the first crystal structures of p53 cancer mutants, which led to the Y220C mutant being used as a paradigm for the development of mutant p53 rescue drugs based on protein stabilization. In 2016, Dr. Joerger joined the group of Prof. Stefan Knapp at the Institute of Pharmaceutical Chemistry at Goethe University, Frankfurt am Main. He is currently a German Research Foundation (DFG)-funded project leader on targeting the p53 mutome for cancer therapy; and co-investigator on a grant from Worldwide Cancer Research for the development of Y220C mutant stabilizers. His other research interests include the evolutionary history of the p53 pathway, epigenetic targets and general principles of molecular interactions.

image of a group member Lena Kilian
Email: kilian (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-42707

Lena Marie Kilian obtained her Bachelor's degree in biology from the Free University Berlin. During that time she spend six month in the SGC in Oxford working with Prof. Stefan Knapp and Jon Elkins on the PAK kinases and later did her Bachelor's Thesis in the Max-Planck-Institute for Colloids and Interfaces with Prof. Christoph Rademacher using 19F and STD NMR for investigating mannose ana-logues as potential drug candidates. She followed up with her Master's degree in molecular biosci-ences at the Goethe-University Frankfurt finishing in 2018. While she did her Master's Thesis at the Merck KGaA in Darmstadt, she focused on validating a method to investigate protein-ligand kinetics as well as changes in the protein conformation called switchSENSE. In November 2018, she started to work in the lab of Prof. Stefan Knapp as a scientific assistant / PhD student elucidating cellular targets and residence time of clinical kinase inhibitors using different techniques, like the NanoBRET cellular target engagement assay and cell migration assays.

image of a group member Andreas Krämer
Email: kraemer (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29872

Andreas Krämer graduated with a diploma in Chemistry from the University of Freiburg in 2012. During his PhD thesis at the University of Darmstadt (2013-2017), he focused on structural studies of bacterial members of the histone deacetylase superfamily (HDAC). After completing his PhD, he joined the group of Stefan Knapp at the SGC Frankfurt as a postdoc. He is currently funded by the Wellcome Trust, working on the structure-based development of selective and potent CaMK1D kinase inhibitors for the treatment of highly aggressive subtypes of breast cancer.

image of a group member Christian Kurz
Email: kurz (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29874

Christian Kurz graduated with a Master's degree in Chemistry at the Johann Wolfgang Goethe University, Frankfurt am Main in 2017. In his Master's thesis project, he developed new synthetic routes for inhibitors of metallo-β-lactamases. He then joined the Knapp group at the SGC site Frankfurt to start his doctoral work on the synthesis of macrocyclic kinase inhibitors.

image of a group member Theresa Mensing
Email: mensing (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29874

Theresa Mensing studied Pharmacy at the Goethe University in Frankfurt. Before graduating in June 2020 she worked in Stefan Knapps group for six month, dealing with the synthesis of macrocyclic protein kinase inhibitors. Since she started her PhD in June 2020 her current research is focused on affecting the selectivity profile of unselective inhibitors.

image of a group member Nebojsa Miletic
Email: miletic (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29496

Nebojsa Miletic graduated with a master´s degree in chemistry at the Johann Wolfgang Goethe University in Frankfurt am Main in 2019. During his master thesis, he worked on the development of pVHL-based PROTACs targeting BRD-containing chromatin remodelling complexes BAF and PBAF for degradation. He joined the group of Prof. Knapp as a PhD student in February 2020 and currently focuses on exploring new ubiquitin E3 ligases fort he development of PROTACs.

image of a group member Mohit Misra
Email: mohitmisra21 (at) gmail.com
Tel: +49 (0)69 798-42707

Mohit obtained his Master's in Biotechnology in New Delhi and a PG diploma in Bioinformatics ‘A’ level. He worked as a Junior Research Fellow at the International Center for Genetic Engineering and Biotechnology (ICGEB) in the Recombinant Gene Products lab led by Dr. Navin Khanna. He moved to Germany to pursue his PhD in the lab of Prof. Hermann Schindelin where he worked at the apex of the ubiquitylation pathway exploring the structure-function relationship of the ubiquitin-activating enzyme (Uba1) and its interactions with multiple E2 enzymes. In addition, he established the structural basis of the variable potency of adenosyl sulfamate inhibitors towards Uba1 which hold promise for cancer therapy. After a brief postdoc in Würzburg, Mohit moved to Frankfurt to join the Dikic lab to pursue his fascination for novel chemistry of ubiquitylation discovered in Legionella. In May 2020, Mohit started team leader position in conjunction with EUbOPEN IMI/ SGC Frankfurt to target the ubiquitin system with new probes in order to develop therapeutics for human diseases.

image of a group member Václav Němec
Email: nemec (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29914

Václav Němec studied Chemistry (BSc.) and later on also Organic Chemistry (MSc. and PhD.) at Masaryk University in Brno, Czech Republic. During his studies in Brno he was involved in several med-chem and chemical biology projects focusing for instance on development of novel kinase inhibitors (CLKs, CK1, ALKs) or inhibitors of Hedgehog signaling. He has spent 7 months in Manchester (UK) on a research stay in laboratories of Prof. David Procter, where he was working on the synthesis of natural product Phaeocaulising based on SmI2 mediated radical cascade reaction. Owing to Jean Marie Lehn scholarship, he spent also one month at EICB Bordeaux (France) in the research group of Prof. Frédéric Friscourt, where he was working on a chemo-enzymatic synthesis of poly-LacNAc chains for binding and study of lectins. In September 2020 he has joined the SGC node at Goethe University in Frankfurt where he is working on development of novel PROTACs and establishment of chemogenomic library.

image of a group member Xiaomin Ni
Email: ni (at) em.uni-frankfurt.de
Tel: +49 (0)69 798-29872

Xiaomin obtained her Master's degree from China Agricultural University in 2014. Then she worked at the Institute of Aging Research (Hangzhou Normal University), investigating the interaction between tryptophanyl-tRNA synthetase and vascular endothelial cadherin. In April 2017, she joined Stefan's team as a PhD student. She is currently working on structural and mechanistic studies of the interaction of FUSE binding protein 1 (FUBP1) with DNA and the development of FUBP1 inhibitors for cancer therapy.

image of a group member David Plano
Email: plano (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-42422

David Plano completed his pharmacy studies at Goethe University Frankfurt in 2020. He did his practical year as a pharmacist and since November 2020 he joined the SGC Frankfurt in the group of Prof. Stefan Knapp in the Cellular Assay Working Group. He focuses his research on discovering the biology of the protein kinases MST1/2/3/4 and specifically on defining their involvement in the Hippo-Pathway using cellular techniques.

image of a group member Marcel Rak
Email: rak (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29317

Marcel Rak graduated in 2018 with a Master's degree in Chemistry at the Johann Wolfgang Goethe University. During his master thesis in the group of Prof. Stefan Knapp at the Institute for Pharmaceutical Chemistry he focused on the synthesis and evaluation of selective inhibitors for the salt-inducible kinase 2 (SIK2). In april 2019 he started his PhD proceeding with the design and synthesis of kinase inhibitors targeting SIK2 and the mammalian STE20-like kinases (MST).

image of a group member Vladimir Rogov
Email: rogov (at) bpc.uni-frankfurt.de
Tel: +49 (0)69 798-29622

Vladimir Rogov obtained his PhD in thermodynamics of protein folding and protein-protein interactions at the Institute of Protein Research, Pushchino, Russia, in the lab of Peter Privalov (1995). He continued his career as a senior scientist at the same institute and as a visiting researcher at University of Frankfurt, Germany (lab of Heinz Rüterjans, 1997-2004). He joined the lab of Volker Dötsch at the Institute of Biophysical Chemistry in 2004. Since 2010 Vladimir leads a research group studying protein-protein and protein-ligand interactions across autophagy and ubiquitination pathways. His main research interests include the characterization of affinity, specificity and driving forces of interactions between human autophagy modifiers (LC3/GABARAP proteins) and a broad spectrum of LIR-containing proteins/peptides by several biophysical and biochemical methods, as well as structural aspects of these interactions. He is also focused on molecular mechanisms of enhancing/reducing of the interactions affinity and specificity by post-translational modifications.

image of a group member Sandra Röhm
Email: roehm (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29313

Sandra Röhm studied Biomedical Chemistry at the Johannes Gutenberg University of Mainz, Germany. She did her diploma thesis at the Max Planck Institute for Polymer Research, where she developed novel fluorescent dyes for staining biomolecules inside living cells. She was awarded the Adolf Todt prize for her studies and graduated with a Diploma degree in Chemistry in 2014. Sandra started her PhD in Stefan Knapp's group in 2015. Her main research interest is to investigate new kinase inhibitors which bind to a unique P-loop conformation of p38 MAPK. Furthermore, she is currently working on the development of a potent and selective probe for the inhibition of discoidin domain receptor tyrosine kinase (DDR).

image of a group member Nadine Ruß
Email: russ (at) chemie.uni-frankfurt.de
Tel: +49 (0)69 798-29317

Nadine Ruß obtained her Master's degree in Chemistry at the University of Frankfurt, Germany, with the research topic "Role of the kinase P-loop in p38 ligand-binding selectivity". In December 2016, she started her PhD in the lab of Prof. Stefan Knapp at the Institute for Pharmaceutical Chemistry, focusing on the synthesis and optimization of type I/II kinase inhibitors targeting MEK7 and the pseudokinase CASK.

image of a group member Krishna Saxena
Email: saxena (at) em.uni-frankfurt.de
Tel: +49 (0)69 798-42701

Krishna Saxena joined the SGC Frankfurt July 2020. Krishna studied Biochemistry in Frankfurt (Germany) followed by a PhD (1999) in heterologous expression of membrane proteins at the Institute of Biochemistry (Frankfurt). Then, he was leading a molecular biology and protein expression group for a collaboration between Aventis Research & Technologies and the Goethe University (1999-2001), later MRPharm (2001-2002), a biotechnology company spin out of Frankfurt University and shortly part of Affinium Pharmaceuticals. The focus of his work became structure-based drug discovery by NMR spectroscopy and X-ray diffraction. From 2003-2011, he was working as a group leader (collaboration Sanofi and Goethe University) to study the family of protein kinases and subsequently to investigate biomedically relevant protein-protein interactions (PPIs) with focus on the modulation of such interactions by low molecular weight ligands guided by NMR technology. Since 2012, he has worked in the drug development platform at the DKTK German Cancer Consortium and for several industrial collaborations.

image of a group member Natalie Schneider
Email: natalie.schneider (at) bio.uni-frankfurt.de

Natalie studied chemistry at the Albert-Ludwigs-Universität Freiburg (Germany) and received her Ph.D in Biochemistry from the Ludwig-Maximilians-Universität München in 1999 with her work carried out at the Max-Planck Institute of Biochemistry, Department of Cell Biology. After postdoctoral research in the area of cell biology at the University of Tokyo (Japan, JSPS fellowship) and the University of Wisconsin - Madison (USA) Natalie moved back to Japan in 2002 to work on heart muscle simulation at Kyoto University. In 2012 she recieved a Master in Computer Science from the University of Advanced Sciences Trier (Germany) with her master thesis done at the Philips Research Laboratories in Aachen. Then she developed software for doctors at CompuGroup Medical in Koblenz. Since August 2017 Natalie works for the SGC Frankfurt where she is mainly responsible for the donated chemical probes website.

image of a group member Martina Scholz
Email: scholz (at) iap.uni-frankfurt.de
Tel: +49 (0)69 798-29303

Martina is managing the office of Stefan Knapp’s group. She did her education in Frankfurt as technic assistant. In the past she was working long years for a plant engineering company in Frankfurt in the IT department for procurement and cost controlling.

image of a group member Martin Schröder
Email: m.schroeder (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29401

Martin Schröder graduated with a degree in Pharmacy from Ludwig-Maximilians-Universität München in 2015. During the last year of his degree, he has spent 6 months at the SGC Oxford working on the biophysical characterization of novel kinase inhibitors. In 2016, he moved to Frankfurt to start as a PhD student at the local SGC site. The focus of his work is on the discovery of features that govern structural flexibility and plasticity in kinases for a better understanding of allosteric kinase regulation.

image of a group member Martin Schwalm
Email: schwalm (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-42422

Martin Schwalm received his MSc in molecular Biotechnology at the Johann-Wolfgang Goethe University in Frankfurt in 2020. For his Master thesis, he joined the Max-Planck Institute for Terrestrial Microbiology (Prof. Dr. Tobias Erb) in Marburg and worked in the field of synthetic metabolism and directed evolution. In october 2020, he started his PhD working in the group of Prof. Dr.Stefan Knapp participating in the SGC Frankfurt and the EUbOPEN consortium. His research interest covers a broad spectrum of topics from drug screening to synthetic biology.

image of a group member Amelie Tjaden
Email: Tjaden (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-42422

Amelie Tjaden studied Pharmacy at Johann Wolfgang Goethe University in Frankfurt. In February 2020 she startet her PhD in the lab of Prof. Stefan Knapp. Her focus lies on the investigation of apoptotic and survival pathways modulated by approved drugs and chemical probes.

image of a group member Claudia Tredup
Email: tredup (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29871

Claudia Tredup studied Biology in Mainz, Germany followed by a PhD in Biochemistry at Christian- Albrechts University in Kiel, Germany. After her postdoc (2013-2014) working on proteolytic en-zymes she moved in 2015 to Frankfurt to investigate the role of proteoglycans in inflammation, innate immunity and renal fibrosis at the Institute of Pharmacology and Toxicology at the Goethe University. In September 2018, she joined the SGC Frankfurt as scientific manager.

image of a group member Marek Wanior
Email: wanior (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29317

Marek Wanior received his MSc in Chemistry at the University of Frankfurt and the Buchmann Institute for Molecular Life Sciences in 2015, where he worked on the cloning and expression of a bacterial multifunctional polyketide synthase, supervised by Prof. Martin Grininger. In August 2015, he joined the group of Prof. Stefan Knapp at the Institute for Pharmaceutical Chemistry, working on the synthesis of bromodomain inhibitors and PROTAC molecules targeting the subfamily VIII. His research is funded by the Else-Kröner-Fresenius Foundation and the Translational Research Innovation Pharma program.

image of a group member Guiqun Wang
Email: wang (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29872

Guiqun Wang obtained his Master's degree from Jilin University in 2017. Then he spent two years of work in the industry, during his time in Amgen R&D center of Asia, his works focus on GPCR Drug discovery, to develop nanobody as agonist and antagonist, while he’s working at Chempartner, he made a major contribution to the discovery of a novel PD-1 antibody which was getting into clinical trial by the FDA later on. In 2020, after he spent one year of PhD research on the cryo-EM structure of NMDA receptors at Max Planck Institute of Biophysics, he turned to join Prof. Stefan Knapp’s group and became a PhD student focused on the research of covalent inhibitors targeting kinases and E3 ubiquitin ligases.

image of a group member Haotian Wang
Email: h.wang (at) em.uni-frankfurt.de
Tel: +49 (0)69 798-42707

image of a group member Tim Weiser
Email: weiser (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29874

Tim Weiser graduated with a Master's degree in Chemistry at the Johann Wolfgang Goethe University in Frankfurt am Main in 2016. During his Master's thesis project, he synthesized dual sEH/FXR modulators to counter nonalcoholic steatohepatitis. Since 2016, he is developing dual BET/HDAC inhibitors in the group of Stefan Knapp at the SGC site Frankfurt.

image of a group member Rezart Zhubi
Email: zhubi (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29872

Rezart Zhubi obtained his Bachelor’s degree in Biotechnology from the University of Tirana (Albania) in 2016. In 2018, he has started his Master's studies at Justus-Liebig University (Giessen) in the field of Agrobiotechnology. From November 2019 to February 2020, he worked in Natural product Discovery in the department of Insect Biotechnology and Bio-resources, in which he participated in a project that focuses on the study of Darobactin, a natural antibiotic that targets gram-negative bacteria produced by nematode symbionts Photorhabdus. In June 2020, he started his master thesis project at Prof. Dr. Stefan Knapp's group focused on Biochemical Characterization of Inhibitors for Ephrin Receptor Kinases. After he pursued his master thesis project, he joined SGC Frankfurt as a Laboratory Technician in the Biochemistry Department working on EUbOPEN Consortium.

Alumni

 

Kathrin Cartsburg (2014 - 2021)

Roberta Tesch (2018 - 2021)

Leonore Novak (2020 - 2021)

Romain Lucas (2018 - 2020)

Anaïs Lucas (2018 - 2020)

Claire Mestdagh (2019 - 2020)

Mishal McAuley (2017 - 2020)

David Heidenreich (2016 - 2019)